Advances in researches on hormonal refractory prostate cancer.
- Author:
Hai-zhu SONG
1
;
Long-bang CHEN
Author Information
1. Department of Oncology, Nanjing General Hospital of Nanjing Command, Nanjing, Jiangsu 210002, China. songhaizhu@163.com
- Publication Type:Journal Article
- MeSH:
Aged;
Androgen Antagonists;
pharmacology;
Biomarkers, Tumor;
analysis;
Drug Resistance, Neoplasm;
Humans;
Male;
Prostatic Neoplasms;
diagnosis;
drug therapy;
pathology
- From:
National Journal of Andrology
2007;13(1):57-60
- CountryChina
- Language:Chinese
-
Abstract:
In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer (HRPC). This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
